RxDoctor Payments Data

Michelle Manias

Nurse Practitioner · Safety Harbor, FLNPI 1497240212

Payments from drug & device makers

$5,121in general payments, 2019–2025

Across 205 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$605
  • Novartis$525
  • Daiichi Sankyo Inc.$301
  • Pfizer$287
  • Johnson & Johnson$252
  • GSK$211
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$4,95897%
  • Education$1633%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,121 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$106,502
Medicare patients
50
Services billed
2,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate11$183,550
EliquisApixaban47$39,675
CreonLipase/Protease/Amylase11$23,503
XareltoRivaroxaban30$22,967
Prochlorperazine Maleate53$1,473
Megestrol Acetate15$900
Doxycycline Hyclate17$797
Ondansetron OdtOndansetron28$626
Anastrozole26$543
Hydroxyurea12$295
Omeprazole11$215
Mirtazapine16$139
Methylprednisolone21$118
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$102
Ciprofloxacin Hcl13$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$525$183,55011 claims
PfizerEliquis$287$39,67547 claims
AbbVieCreon$172$23,50311 claims
Johnson & JohnsonXarelto$252$22,96730 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$6816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Safety Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →